Correlation Between Mineralys Therapeutics, and GlycoMimetics

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and GlycoMimetics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and GlycoMimetics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and GlycoMimetics, you can compare the effects of market volatilities on Mineralys Therapeutics, and GlycoMimetics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of GlycoMimetics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and GlycoMimetics.

Diversification Opportunities for Mineralys Therapeutics, and GlycoMimetics

0.16

Correlation Coefficient

Mineralys Therapeutics,  GlycoMimetics

Average diversification

The 3 months correlation between Mineralys and GlycoMimetics is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and GlycoMimetics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GlycoMimetics and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with GlycoMimetics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GlycoMimetics has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and GlycoMimetics go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and GlycoMimetics

Given the investment horizon of 90 days Mineralys Therapeutics, is expected to generate 12.43 times less return on investment than GlycoMimetics. But when comparing it to its historical volatility, Mineralys Therapeutics, Common is 6.07 times less risky than GlycoMimetics. It trades about 0.04 of its potential returns per unit of risk. GlycoMimetics is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest  16.00  in GlycoMimetics on September 18, 2024 and sell it today you would earn a total of  7.31  from holding GlycoMimetics or generate 45.69% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  GlycoMimetics

Mineralys Therapeutics,

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.

GlycoMimetics

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in GlycoMimetics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, GlycoMimetics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Mineralys Therapeutics, and GlycoMimetics

The main advantage of trading using opposite Mineralys Therapeutics, and GlycoMimetics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, GlycoMimetics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GlycoMimetics will offset losses from the drop in GlycoMimetics' long position.

The idea behind Mineralys Therapeutics, Common and GlycoMimetics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.